期刊
EUROPEAN JOURNAL OF CANCER
卷 48, 期 11, 页码 1739-1749出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2011.07.016
关键词
Pheochromocytoma; Paraganglioma; Metastases; Methoxytyramine; Dopamine; Metanephrines; Catecholamines; Succinate dehydrogenase type B
类别
资金
- Intramural programmes of the Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Center for Cancer Research, National Cancer Institute, NIH
- European Union [HEALTH-F2-2010-259735]
- Deutsche Forschungsgesellschaft
- Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research
Background: There are currently no reliable biomarkers for malignant pheochromocytomas and paragangliomas (PPGLs). This study examined whether measurements of catecholamines and their metabolites might offer utility for this purpose. Methods: Subjects included 365 patients with PPGLs, including 105 with metastases, and a reference population of 846 without the tumour. Eighteen catecholamine-related analytes were examined in relation to tumour location, size and mutations of succinate dehydrogenase subunit B (SDHB). Results: Receiver-operating characteristic curves indicated that plasma methoxytyramine, the O-methylated metabolite of dopamine, provided the most accurate biomarker for discriminating patients with and without metastases. Plasma methoxytyramine was 4.7-fold higher in patients with than without metastases, a difference independent of tumour burden and the associated 1.6- to 1.8-fold higher concentrations of norepinephrine and normetanephrine. Increased plasma methoxytyramine was associated with SDHB mutations and extra-adrenal disease, but was also present in patients with metastases without SDHB mutations or those with metastases secondary to adrenal tumours. High risk of malignancy associated with SDHB mutations reflected large size and extra-adrenal locations of tumours, both independent predictors of metastatic disease. A plasma methoxytyramine above 0.2 nmol/L or a tumour diameter above 5 cm indicated increased likelihood of metastatic spread, particularly when associated with an extra-adrenal location. Conclusion: Plasma methoxytyramine is a novel biomarker for metastatic PPGLs that together with SDHB mutation status, tumour size and location provide useful information to assess the likelihood of malignancy and manage affected patients. (C) 2011 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据